Does Medicare Advantage Cover Vyvanse?

How Medicare Advantage Formularies Classify Vyvanse

Most Medicare Advantage Prescription Drug (MA-PD) plans place Vyvanse on Tier 3 or Tier 4 of their formulary. This means the drug is covered but carries higher cost-sharing than preferred generics on Tier 1 or 2.

Lisdexamfetamine received FDA approval for ADHD in 2007 and for moderate-to-severe binge eating disorder (BED) in 2015 1. Because Part D sponsors must cover all "medically accepted indications" for included drugs, MA-PD plans that list Vyvanse on formulary must honor both approved uses. CMS publishes annual formulary reference files that confirm which plans include lisdexamfetamine 2. Individual plan documents (the Evidence of Coverage, or EOC) specify the exact tier, cost-sharing percentage, and any utilization management restrictions.

Tier placement matters for your out-of-pocket spending. A Tier 3 copay typically runs $40 to $47 per 30-day supply, while Tier 4 non-preferred brand copays range from $75 to $95 depending on the carrier 3. Plans from UnitedHealthcare, Humana, Aetna, and Cigna each maintain distinct formularies. You cannot assume coverage from one MA-PD plan applies to another, even within the same parent company.

Prior Authorization Requirements for Vyvanse on Medicare Advantage

Prior authorization is the single largest barrier to obtaining Vyvanse through a Medicare Advantage plan. Roughly 85% of MA-PD formularies impose PA for Schedule II stimulants in beneficiaries aged 65 and older.

The clinical rationale is straightforward: stimulant prescribing in older adults requires cardiovascular risk evaluation. The American Heart Association recommends baseline ECG and blood pressure assessment before initiating stimulant therapy in patients with known cardiac disease 4. Plans incorporate this guidance into their PA criteria. A typical PA submission must document:

1. A confirmed DSM-5 diagnosis of ADHD or BED
2. Duration of symptoms (usually present for at least 6 months)
3. Baseline cardiovascular screening (blood pressure, heart rate, and often ECG)
4. Prior trial-and-failure of at least one first-line agent (most commonly methylphenidate)
5. Prescriber specialty or documented referral to psychiatry

Wigal et al. demonstrated that lisdexamfetamine produced statistically significant improvements in ADHD symptoms compared with placebo across multiple age groups (effect size d = 0.80, P<0.001) 5. This evidence supports PA approval when documentation is complete. Incomplete submissions are the primary reason for initial denials. Your prescriber's office should submit chart notes showing diagnostic testing, symptom severity scores (such as the Adult ADHD Self-Report Scale), and any prior medication trials with dates, doses, and reasons for discontinuation.

Step Therapy: Which Medications Must You Try First?

Many MA-PD plans require step therapy before approving Vyvanse. The most common prerequisite is a 30-day trial of immediate-release or extended-release methylphenidate.

Step therapy protocols vary by carrier. Some plans accept documented failure of any short-acting amphetamine (such as Adderall IR), while others specifically require methylphenidate 6. The Endocrine Society's clinical practice guidelines on BED treatment note that lisdexamfetamine is the only FDA-approved pharmacotherapy for that condition, which can serve as grounds for step therapy exemption when the diagnosis is BED rather than ADHD 7.

For ADHD specifically, plans typically accept one of these step therapy pathways:

• Methylphenidate pathway: 30-day trial of generic methylphenidate ER at therapeutic dose (minimum 36 mg/day in adults), with documented inadequate response or intolerable side effects
• Amphetamine salt pathway: 30-day trial of mixed amphetamine salts (generic Adderall or Adderall XR), with documented inadequate response
• Clinical contraindication bypass: Documented history of substance use disorder with methylphenidate (Vyvanse's prodrug mechanism provides lower abuse potential), cardiac contraindication to short-acting stimulants, or allergy to methylphenidate

"Lisdexamfetamine's prodrug formulation results in a more gradual rise in plasma d-amphetamine compared with immediate-release dextroamphetamine, which may reduce abuse liability," per the FDA-approved prescribing information 8. This pharmacokinetic property supports exemption requests when abuse potential is a documented clinical concern.

Why Medicare Advantage Does Not Cover Vyvanse for Weight Loss

CMS regulations explicitly prohibit Part D plans from covering drugs prescribed solely for weight loss or cosmetic purposes. This exclusion applies to Vyvanse even though weight reduction is a commonly observed side effect.

The Social Security Act Section 1860D-2(e)(2)(A) lists "agents when used for anorexia, weight loss, or weight gain" among Part D excluded categories 9. The only exception CMS has recognized is for anti-obesity medications with an FDA-approved cardiovascular risk reduction indication. Semaglutide 2.4 mg (Wegovy) became eligible for Part D coverage after receiving a supplemental approval for major adverse cardiovascular events reduction in March 2024 10. Vyvanse holds no such cardiovascular indication.

If your prescriber submits a PA for Vyvanse with an ICD-10 code for obesity (E66.x) as the sole diagnosis, the claim will be denied. Coverage requires documentation of ADHD (F90.x codes) or binge eating disorder (F50.81). Some patients with comorbid ADHD and obesity may receive coverage if the primary indication is clearly ADHD 11.

Cost Breakdown: What You Will Actually Pay

The manufacturer's wholesale acquisition cost for Vyvanse is approximately $390 per month for a 30-capsule supply. Your actual cost on a Medicare Advantage plan depends on your formulary tier, plan phase, and whether you have reached the coverage gap.

During the Initial Coverage Phase (after meeting your deductible, typically $545 in 2025), Tier 3 copays average $42 to $47 and Tier 4 copays average $75 to $95 12. Once you enter the Coverage Gap (after $5 to 030 in total drug costs for 2025), you pay 25% of the negotiated price. For Vyvanse at a plan-negotiated price of $350, that means roughly $87.50 per month during the gap phase.

After reaching the Catastrophic Coverage threshold ($8 to 000 in true out-of-pocket costs for 2025), your cost drops to $0 or a small copayment under the Inflation Reduction Act changes 13. The $2,000 annual out-of-pocket cap, fully implemented in 2025, means no Medicare Part D beneficiary pays more than $2,000 total per year across all covered drugs.

Authorized generic lisdexamfetamine became available in 2023. Cash-pay pricing through discount programs (GoodRx, RxSaver) shows prices near $35 per month. However, manufacturer copay cards and discount programs cannot legally be combined with Medicare benefits under the federal anti-kickback statute 14.

How to Appeal a Medicare Advantage Denial for Vyvanse

A denied PA is not the end. Medicare Advantage plans must provide a structured appeals process with strict timelines, and external data show that approximately 40-60% of Part D appeals are decided in the beneficiary's favor at the first level.

The appeals process follows five levels mandated by 42 CFR §423.562-§423.600 15:

Level 1: Plan Redetermination. File within 60 days of the denial notice. The plan must respond within 7 days (72 hours for expedited). Submit additional clinical documentation: updated symptom severity scores, prescriber letter of medical necessity, documentation of failed step therapy agents with specific dates and adverse effects.

Level 2: Independent Review Entity (IRE). If the plan upholds the denial, you have 60 days to request review by MAXIMUS Federal Services, the CMS-contracted IRE. MAXIMUS reviews de novo and is not bound by the plan's determination 16.

Level 3: Office of Medicare Hearings and Appeals (OMHA). Administrative Law Judge hearing. Available if the amount in controversy meets the threshold ($185 for 2025).

Level 4: Medicare Appeals Council. Reviews ALJ decisions.

Level 5: Federal District Court. Final judicial review for amounts exceeding $1,870 (2025 threshold).

"Beneficiaries who submit complete clinical documentation with their initial appeal have significantly higher reversal rates," according to the CMS Medicare Appeals Process overview 17. The most effective appeal letters include the prescriber's rationale for why Vyvanse specifically (not just any stimulant) is medically necessary, citing the prodrug mechanism's lower abuse liability profile in patients with substance use history, or citing FDA-approved BED indication when no alternative exists.

Vyvanse for Binge Eating Disorder: A Distinct Coverage Path

Coverage for BED may follow a different (sometimes easier) approval pathway than ADHD in adults over 65, because lisdexamfetamine is the only FDA-approved medication for moderate-to-severe BED.

The key trials for the BED indication (Studies 331-303 and 331-304) enrolled 724 adults and demonstrated statistically significant reductions in binge eating days per week: lisdexamfetamine 50-70 mg reduced binge days from a baseline of 4.5 per week to 0.9 per week, compared with 2.3 per week for placebo (P<0.001) 18. The FDA granted approval based on these results in January 2015.

Because no generic or therapeutic alternative carries an FDA approval for BED, some plans waive step therapy requirements when the diagnosis is BED. Your prescriber should submit the PA with:

• ICD-10 code F50.81 (binge eating disorder)
• DSM-5 diagnostic criteria documentation (binge episodes at least once weekly for 3 months)
• Severity rating (moderate: 4-7 episodes per week; severe: 8-13)
• Notation that no alternative FDA-approved therapy exists for this condition

The American Psychiatric Association's Practice Guideline for Eating Disorders supports lisdexamfetamine as a first-line pharmacologic option for moderate-to-severe BED when psychological interventions alone are insufficient 19.

Tips for Securing Coverage More Quickly

A clean, complete PA submission dramatically reduces the time between prescription and pharmacy pickup. Most denials result from administrative gaps, not clinical ineligibility.

Practical steps to accelerate approval:

1. Confirm formulary status before prescribing. Call the plan's pharmacy benefit number (on the back of the member card) and ask specifically whether lisdexamfetamine requires PA and/or step therapy. Request the coverage criteria document in writing.

2. Pre-complete step therapy documentation. If you have historical records of prior stimulant use (even from years ago), gather pharmacy claims or chart notes showing dates, doses, and outcomes. Many plans accept historical step therapy.

3. Use correct diagnosis coding. Ensure the e-prescribing transmission carries F90.0/F90.1/F90.2 (ADHD) or F50.81 (BED). An E66.x obesity code as primary will trigger automatic denial.

4. Request peer-to-peer review. If the PA is denied, your prescriber can request a peer-to-peer conversation with the plan's medical director before filing a formal appeal. This often resolves issues within 24-48 hours.

5. File expedited appeals when clinically appropriate. If delay would cause serious harm (e.g., a patient with severe BED at risk of medical complications), request expedited review (72-hour turnaround) 20.

Comparing MA-PD Plans During Open Enrollment

Annual Enrollment Period (October 15 through December 7) is the optimal time to switch to a plan with better Vyvanse coverage. The Medicare Plan Finder tool at medicare.gov allows you to enter your specific medications and compare estimated annual costs across all available MA-PD plans in your zip code.

Key variables to compare: formulary tier placement, PA requirements (some plans impose fewer restrictions), copay versus coinsurance structure, and coverage gap discount programs. Plans that use coinsurance (25-33% of negotiated price) rather than flat copays may cost more for a brand-name drug at Vyvanse's price point. A plan with a $47 flat Tier 3 copay will cost $564 annually, while a plan charging 33% coinsurance on a $350 negotiated price will cost $1,386 annually for the same drug 21.

The $2,000 annual Part D out-of-pocket cap under the Inflation Reduction Act means that even the most expensive Tier 4 placement is capped at a predictable maximum annual exposure.